Gapping up
In reaction to strong earnings/guidance:
- BCRX +1.6%
M&A news:
- NITE +67.1% (o be acquired by Biogen (BIIB) for $25.50/share in cash)
Select biotech related names showing strength:
- RKDA +26.2%, SGMO +10.4%, PGNX +5.1%, TRVN +3.7%
Select Chinese stocks trading higher:
- KNDI +3.2%, VIPS +3%, BZUN +2.4%, MOMO +2.4%, CTRP +2.2%, WB +2.2%, SOHU +1.7%, JD +1.7%, BABA +1.6%, NTES +1.2%, BIDU +1.2%
Other news:
- ASND +60.2% (announces positive top-line results from phase 3 heiGHt Trial)
- AVXL +9.2% (publication by independent scientific group of new preclinical data for ANAVEX2-73)
- ODP +9.6% (Co and Alibaba.com (BABA) announced a strategic collaboration)
- ATNX +7.5% (presents results from two Phase III studies of KX2-391 ointment in the treatment of actinic keratosis)
- CSII +7% (to join S&P SmallCap 600)
- SLDB +6.2% (positive Barrons article)
- RGNX +5.9% (positive Barrons article)
- WRE +5.7% (to join S&P SmallCap 600)
- XON +4.3% (announces a strategic licensing agreement with Surterra Wellness 'to utilize Intrexon's Botticelli)
- VYGR +2.4% (positive Barrons article)
- NKTR +2.3% (presents preliminary immune activation, safety and clinical activity data from the ongoing dose-escalation stage of the REVEAL Study)
- QURE +2.1% (positive Barrons article)
- TSLA +1.2% (CEO Elon Musk tweets Model Y event will be March 14)
- TEVA +1% (announces U.S. launch of authorized generic of Flector Patch) .
Analyst comments:
- ON +2.5% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- KHC +2% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- IMMU +1.8% (initiated with a Buy at H.C. Wainwright)
- HAS +1.7% (upgraded to Market Perform from Underperform at BMO Capital Markets)
- FL +1.1% (upgraded to Buy from Hold at Pivotal Research Group)